Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
DDLS
MCID: DDF001
MIFTS: 48

Dedifferentiated Liposarcoma (DDLS)

Categories: Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Dedifferentiated Liposarcoma

About this section

MalaCards integrated aliases for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 12 58 15 17
Liposarcoma, Dedifferentiated 71
Liposarcoma Dedifferentiated 54
Ddls 58

Characteristics:

Orphanet epidemiological data:

58
dedifferentiated liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0080531
NCIt 49 C3704
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0205824
Orphanet 58 ORPHA99970
UMLS 71 C0205824
Sources

Summaries for Dedifferentiated Liposarcoma

About this section
Disease Ontology : 12 A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells.

MalaCards based summary : Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to pleomorphic lipoma and fibrous histiocytoma. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ifosfamide and Isophosphamide mustard have been mentioned in the context of this disorder. Affiliated tissues include bone, adipocyte and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Dedifferentiated Liposarcoma

About this section

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
# Related Disease Score Top Affiliating Genes
1 pleomorphic lipoma 31.8 MDM2 HMGA2 CDK4 CD34
2 fibrous histiocytoma 31.8 TP53 MYOG KIT DES CD34
3 spindle cell sarcoma 31.7 MYOG MDM2 DES CD34
4 malignant fibrous histiocytoma 31.5 TP53 MYOG MDM2 MB KIT DES
5 well-differentiated liposarcoma 31.5 TP53 MYOG MDM2 KIT HMGA2 FRS2
6 pleomorphic liposarcoma 31.4 MDM2 KIT DES DDIT3 CDKN2A CDK4
7 osteogenic sarcoma 31.3 TP53 RB1 MDM2 IGF1R CDKN2A CDK4
8 sclerosing liposarcoma 31.3 MDM2 CD34
9 myxoid liposarcoma 31.2 TP53 MDM2 IGF1R HMGA2 DDIT3 CDK4
10 malignant mesenchymoma 31.2 MYOG MDM2 MB DES CD34
11 embryonal sarcoma 31.2 TP53 MYOG MDM2 KIT DES CDK4
12 retroperitoneal sarcoma 31.2 MYOG MDM2 KIT CDK4 CD34
13 lipomatosis, multiple 31.2 PTEN MDM2 KIT HMGA2 DES DDIT3
14 pseudosarcomatous fibromatosis 31.2 MYOG DES CD34
15 spindle cell liposarcoma 31.2 MDM2 DDIT3 CDK4 CD34
16 mixed liposarcoma 31.2 MDM2 DDIT3 CDK4 CD34
17 mesenchymal cell neoplasm 31.1 TP53 MYOG KIT HMGA2 CD34
18 mediastinum liposarcoma 31.1 MDM2 CDKN2A CDK4
19 inflammatory myofibroblastic tumor 31.1 TP53 MYOG MDM2 KIT DES CDK4
20 connective tissue benign neoplasm 31.0 TP53 MDM2 KIT CDK4 CD34
21 inflammatory liposarcoma 31.0 MDM2 CDKN2A CD34
22 cellular myxoid liposarcoma 31.0 MDM2 DDIT3 CDK4
23 myxofibrosarcoma 31.0 TP53 MYOG MET MDM2 KIT DES
24 gallbladder sarcoma 31.0 MYOG DES
25 extraosseous osteosarcoma 30.9 MYOG MDM2 CDK4 CD34
26 leukemia, acute lymphoblastic 3 30.9 TP53 CDKN2A CD34
27 familial retinoblastoma 30.9 TP53 RB1 MDM2 CDKN2A CDK4
28 embryonal rhabdomyosarcoma 30.9 TP53 MYOG MDM2 MB DES CDK4
29 ring chromosome 30.9 TP53 MDM2 IGF1R HMGA2 CDK4
30 liposarcoma 30.9 TP53 STAT6 RB1 PTEN PPARG MYOG
31 intravenous leiomyomatosis 30.9 HMGA2 DES CD34
32 follicular dendritic cell sarcoma 30.8 MDM2 KIT CD34
33 infiltrating lipoma 30.8 MDM2 HMGA2 CDK4 CD34
34 heart sarcoma 30.8 MYOG MDM2 KIT CD34
35 neurilemmoma 30.7 KIT DES CD34
36 gastrointestinal stromal tumor 30.7 TP53 PTEN KIT DES CDKN2A CD34
37 meningioma, familial 30.7 TP53 STAT6 PTEN CDKN2A CD34
38 leiomyosarcoma 30.7 TP53 RB1 MYOG MDM2 MB KIT
39 spindle cell lipoma 30.7 RB1 MDM2 DES CDK4 CD34
40 connective tissue cancer 30.7 TP53 PTEN MDM2 CDKN2A CDK4 CD34
41 retroperitoneal leiomyosarcoma 30.6 KIT CD34
42 lynch syndrome 30.6 TP53 PTEN MDM2 CDKN2A
43 myoma 30.6 TP53 KIT HMGA2 CD34
44 sarcoma 30.5 TP53 RB1 MYOG MET MDM2 KIT
45 li-fraumeni syndrome 30.5 TP53 RB1 PTEN MDM2 CDKN2A CDK4
46 retinoblastoma 30.5 TP53 RB1 PPARG MET MDM2 CEBPA
47 rhabdomyosarcoma 30.4 TP53 RB1 PTEN MYOG MET MDM2
48 malignant peripheral nerve sheath tumor 30.3 TP53 MYOG MET MDM2 KIT IGF1R
49 adenocarcinoma 30.0 TP53 RB1 PTEN MET MDM2 KIT
50 aortic malignant tumor 10.7 MDM2 CD34

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to Dedifferentiated Liposarcoma
Sources

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

About this section

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.09 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.09 MDM2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.09 MDM2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.09 IGF1R MDM2 STAT6
5 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.09 RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.09 RB1 STAT6
7 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.09 RB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.09 STAT6
9 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.09 RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.09 MDM2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-33 10.09 STAT6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.09 STAT6
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.09 MDM2 RB1 STAT6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.09 CEBPA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.09 RB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.09 STAT6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.09 IGF1R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.09 MDM2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.09 CEBPA STAT6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.09 STAT6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.09 IGF1R
22 Decreased substrate adherent cell growth GR00193-A-1 10 IGF1R KIT MET
23 Decreased substrate adherent cell growth GR00193-A-2 10 CDK4 KIT
24 Decreased substrate adherent cell growth GR00193-A-3 10 CDK4 MET
25 Decreased substrate adherent cell growth GR00193-A-4 10 CDK4 IGF1R KIT MET
26 Reduced mammosphere formation GR00396-S 9.32 CD34 CDK4 CEBPA DDIT3 DES FRS2
27 Decreased viability in glioblastoma multiforme (GBM) lineage; decreased viability in pancreas lineage GR00235-A 8.85 PPARG

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 CD34 CDK4 CDKN2A CEBPA DDIT3 DES
2 behavior/neurological MP:0005386 10.51 CDK4 CDKN2A CEBPA DDIT3 DES IGF1R
3 cardiovascular system MP:0005385 10.5 CDK4 CDKN2A CEBPA DDIT3 DES FRS2
4 homeostasis/metabolism MP:0005376 10.5 CD34 CDK4 CDKN2A CEBPA DDIT3 DES
5 growth/size/body region MP:0005378 10.49 CDK4 CDKN2A CEBPA DDIT3 FRS2 IGF1R
6 embryo MP:0005380 10.42 CDK4 CDKN2A FRS2 IGF1R KIT MB
7 hematopoietic system MP:0005397 10.42 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
8 endocrine/exocrine gland MP:0005379 10.41 CDK4 CDKN2A CEBPA DDIT3 IGF1R KIT
9 mortality/aging MP:0010768 10.41 CDK4 CDKN2A CEBPA DES FRS2 IGF1R
10 immune system MP:0005387 10.4 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
11 integument MP:0010771 10.36 CD34 CDK4 CDKN2A CEBPA IGF1R KIT
12 liver/biliary system MP:0005370 10.34 CDK4 CDKN2A CEBPA DDIT3 IGF1R KIT
13 muscle MP:0005369 10.34 CDK4 CDKN2A CEBPA DES IGF1R KIT
14 neoplasm MP:0002006 10.32 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
15 digestive/alimentary MP:0005381 10.31 CDK4 CDKN2A CEBPA IGF1R KIT MDM2
16 nervous system MP:0003631 10.27 CDK4 CDKN2A DDIT3 FRS2 IGF1R KIT
17 adipose tissue MP:0005375 10.24 CEBPA DDIT3 IGF1R MYOG PPARG PTEN
18 craniofacial MP:0005382 10.22 CDK4 FRS2 IGF1R KIT MDM2 MET
19 limbs/digits/tail MP:0005371 10.14 FRS2 IGF1R KIT MDM2 MET PTEN
20 hearing/vestibular/ear MP:0005377 10.13 DDIT3 FRS2 IGF1R KIT PPARG RB1
21 normal MP:0002873 10.1 CDK4 CEBPA KIT MDM2 MET MYOG
22 no phenotypic analysis MP:0003012 10.09 CDKN2A CEBPA KIT MDM2 MET MYOG
23 renal/urinary system MP:0005367 10.02 CDK4 CEBPA KIT MDM2 MET PPARG
24 reproductive system MP:0005389 10 CDK4 CDKN2A CEBPA IGF1R KIT MDM2
25 pigmentation MP:0001186 9.91 CDK4 CDKN2A KIT MDM2 PTEN RB1
26 respiratory system MP:0005388 9.9 CDKN2A CEBPA IGF1R KIT MB MET
27 skeleton MP:0005390 9.7 CDK4 CDKN2A FRS2 IGF1R KIT MDM2
28 vision/eye MP:0005391 9.36 CDK4 CDKN2A CEBPA FRS2 KIT MET
Sources

Drugs & Therapeutics for Dedifferentiated Liposarcoma

About this section

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Isophosphamide mustard Phase 3 0
3
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
4
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
6
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
7
Ipilimumab Approved Phase 2 477202-00-9
8
nivolumab Approved Phase 2 946414-94-4
9 Alkylating Agents Phase 2
10 Immunosuppressive Agents Phase 2
11 Immunologic Factors Phase 2
12 Protein Kinase Inhibitors Phase 2
13 Immunoglobulins Phase 2
14 Antibodies Phase 2
15 Antibodies, Monoclonal Phase 2
16 Antineoplastic Agents, Immunological Phase 2
17
Ixazomib Approved, Investigational Phase 1 1072833-77-2
18
protease inhibitors Phase 1
19 HIV Protease Inhibitors Phase 1
20 Proteasome Inhibitors Phase 1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
2 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
3 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
4 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
5 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
6 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
7 Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Recruiting NCT03114527 Phase 2 Ribociclib;Everolimus
8 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2
9 A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated and/or Dedifferentiated Liposarcoma Recruiting NCT04438824 Phase 2 INCMGA00012;Palbociclib
10 Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration Recruiting NCT04040205 Phase 2 Abemaciclib
11 Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma Active, not recruiting NCT01913652 Phase 2 Cabazitaxel
12 Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma Active, not recruiting NCT02846987 Phase 2 Abemaciclib
13 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma Active, not recruiting NCT02500797 Phase 2
14 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
15 A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Withdrawn NCT00969917 Phase 2 IPI-504
16 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer Completed NCT01636479 Phase 1 SAR405838
17 A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma Recruiting NCT04242238 Phase 1 DCC-3014;Avelumab
18 A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma Not yet recruiting NCT03880123 Phase 1 Selinexor;Ixazomib
19 Correlation of DDLS Grading to OCT, HRT, and HVF Completed NCT00430287
20 RAPDx Pupillography for Early Detection of Glaucoma Completed NCT02526693
21 The FGF/FGFR Signalling Pathway: a Novel Therapeutic Target in Liposarcomas Recruiting NCT03303885
22 REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group Recruiting NCT03838718
23 Timing of Glaucoma Drainage Device Implantation With Boston Keratoprosthesis Surgery Recruiting NCT02084745

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Sources

Genetic Tests for Dedifferentiated Liposarcoma

About this section
Sources

Anatomical Context for Dedifferentiated Liposarcoma

About this section

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

40
Bone, Adipocyte, Colon, Lung, Breast, Lymph Node, Kidney
Sources

Publications for Dedifferentiated Liposarcoma

About this section

Articles related to Dedifferentiated Liposarcoma:

(show top 50) (show all 662)
# Title Authors PMID Year
1
Well-differentiated and dedifferentiated liposarcomas. 54 61
19688222 2010
2
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 54 61
19946100 2009
3
SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. 54 61
19454362 2009
4
Other targetable sarcomas. 54 61
19664496 2009
5
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 61 54
18820664 2009
6
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 54 61
18836421 2009
7
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 54 61
18500263 2008
8
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 54 61
18204431 2008
9
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 54 61
17638873 2007
10
[Extragastrointestinal stromal tumors: a report of 4 cases]. 61 54
16472759 2006
11
alpha-fetoprotein expression in a dedifferentiated liposarcoma. 61 54
16489442 2006
12
Alterations of the RB1 gene in dedifferentiated liposarcoma. 61 54
15933756 2005
13
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 54 61
16160477 2005
14
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 61 54
12640106 2003
15
Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. 61 54
11480734 2001
16
Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. 54 61
11484509 2001
17
Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. 54 61
11518050 2001
18
Fibrohistiocytic differentiation in subcutaneous fatty tumors. Study of spindle cell, pleomorphic, myxoid, and atypical lipoma and dedifferentiated liposarcoma cases composed in part of CD34+ fibroblasts and FXIIIa+ histiocytes. 54 61
9331894 1997
19
Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. 54 61
9071997 1997
20
Extracellular vesicle cross-talk in the liposarcoma microenvironment. 61
32470489 2020
21
MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction. 61
32559641 2020
22
Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. 61
32576580 2020
23
Dedifferentiated liposarcoma of the spermatic cord: Case report and review of literature. 61
32563833 2020
24
Dedifferentiated Liposarcoma of the Descending Colon: A Case Report and Review of the Literature. 61
32300935 2020
25
Giant polypoid masses on endoscopy with a surprising nature: dedifferentiated liposarcoma. 61
31923408 2020
26
Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old. 61
31801397 2020
27
Expanding the differential of cutaneous epithelioid tumors: A case of dedifferentiated liposarcoma with epithelioid features involving the skin, with review of the literature. 61
31995237 2020
28
Prognostic Value of Myogenic Differentiation in Dedifferentiated Liposarcoma. 61
31985499 2020
29
Outcomes of palliative-intent surgery in retroperitoneal sarcoma-Results from the US Sarcoma Collaborative. 61
32167587 2020
30
Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. 61
31892479 2020
31
Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma. 61
32367501 2020
32
Low-grade Osteosarcomatous Dedifferentiation of an Atypical Lipomatous Tumor in a Pediatric Patient. 61
31739757 2020
33
MDM2-positive papillary sarcomatoid renal cell carcinoma: a potential diagnostic pitfall. 61
31732813 2020
34
Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma With Features Mimicking Spindle Cell Lipoma. 61
31672072 2020
35
Recombinant Methioninase Combined With Tumor-targeting Salmonella typhimurium A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. 61
32366396 2020
36
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. 61
32145342 2020
37
Diaphragmatic liposarcoma with gall bladder invasion: CT and MRI findings. 61
32140198 2020
38
A case of retroperitoneal dedifferentiated liposarcoma successfully treated by neoadjuvant chemotherapy and subsequent surgery. 61
32448975 2020
39
Dedifferentiated Liposarcoma With Meningothelial-Like Whorls: Five Additional Cases and Review of the Literature. 61
32419561 2020
40
Well-Differentiated/Dedifferentiated Liposarcoma Arising in the Upper Aerodigestive Tract: 8 Cases Mimicking Non-adipocytic Lesions. 61
32410132 2020
41
Thoracoscopic resection of a huge esophageal dedifferentiated liposarcoma: A case report. 61
32420304 2020
42
Ultrasonographic findings and diagnosis of omental dedifferentiated liposarcoma: a case report. 61
32269642 2020
43
Deceptive Giant Dedifferentiated Liposarcoma of the Esophagus: An Extremely Rare Surgical Case. 61
31526158 2020
44
Novel CTNND2-TERT fusion in a spindle cell liposarcoma. 61
32352179 2020
45
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. 61
31201607 2020
46
An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas. 61
32092619 2020
47
Primary Orbital Dedifferentiated Liposarcoma: A Case Report. 61
32339743 2020
48
STAT6 Expression in Solitary Fibrous Tumor and Histologic Mimics: a Single Institution Experience. 61
30664532 2020
49
Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. 61
31825533 2020
50
Primary gastrointestinal liposarcoma-a clinicopathological study of 8 cases of a rare entity. 61
31884085 2020
Sources

Variations for Dedifferentiated Liposarcoma

About this section
Sources

Expression for Dedifferentiated Liposarcoma

About this section
Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.
Sources

Pathways for Dedifferentiated Liposarcoma

About this section

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.83 TP53 STAT6 RB1 PTEN MET MDM2
2
GPCR Pathway 63
Show member pathways
 13.72 TP53 STAT6 RB1 MET MDM2 KIT
3
Akt Signaling 63
Show member pathways
 13.43 TP53 STAT6 PTEN MET MDM2 KIT
4
Cellular Senescence (REACTOME) 65
Show member pathways
 13.15 TP53 RB1 MDM2 HMGA2 CDKN2A CDK4
5
GAB1 signalosome 65
Show member pathways
 13.13 TP53 PTEN MET MDM2 KIT FRS2
6
Phospholipase-C Pathway 63
Show member pathways
 13.08 TP53 PTEN MET MDM2 KIT IGF1R
7
PI3K-Akt signaling pathway 36
Show member pathways
 13.01 TP53 RB1 PTEN MET MDM2 KIT
8
MAPK signaling pathway 36 1
12.78 TP53 MET KIT IGF1R DDIT3
9
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.77 TP53 PTEN MET MDM2 KIT FRS2
10
Gastric cancer 36
Show member pathways
 12.76 TP53 RB1 PTEN MET KIT IGF1R
11
Apoptosis Modulation and Signaling 1
Show member pathways
 12.72 TP53 MDM2 IGF1R DDIT3 CDKN2A
12
Endometrial cancer 36
Show member pathways
 12.7 TP53 RB1 PTEN PPARG MDM2 KIT
13
ErbB signaling pathway 36 1
Show member pathways
 12.64 TP53 PTEN MET MDM2 IGF1R
14
Glioma 36
Show member pathways
 12.63 TP53 RB1 PTEN MET MDM2 IGF1R
15
Mitotic G1-G1/S phases 65
Show member pathways
 12.59 TP53 RB1 MDM2 CDKN2A CDK4
16
MicroRNAs in cancer 36
12.57 TP53 PTEN MET MDM2 HMGA2 CDKN2A
17
Glucose / Energy Metabolism 4
12.56 PTEN PPARG MB IGF1R CEBPA
18
DNA Damage 4
12.54 TP53 RB1 MDM2 CDKN2A CDK4
19
Apoptosis Pathway 70
Show member pathways
 12.45 TP53 MET MDM2 IGF1R
20
Cell cycle 36 1
12.42 TP53 RB1 MDM2 CDKN2A CDK4
21
DNA Damage Response 1
Show member pathways
 12.42 TP53 RB1 PTEN MDM2 CDKN2A CDK4
22
Human T-cell leukemia virus 1 infection 36
12.38 TP53 RB1 PTEN CDKN2A CDK4
23
Development IGF-1 receptor signaling 22
Show member pathways
 12.38 TP53 STAT6 PTEN MET MDM2 IGF1R
24
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.37 TP53 RB1 CDKN2A CDK4
25
Proteoglycans in cancer 36
12.35 TP53 MET MDM2 IGF1R FRS2
26
Viral carcinogenesis 36
12.34 TP53 RB1 MDM2 CDKN2A CDK4
27
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.33 TP53 PTEN MDM2 IGF1R
29
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.29 TP53 RB1 MET KIT IGF1R
30
p53 Signaling 63
Show member pathways
 12.28 TP53 RB1 PTEN MDM2 CDK4
31
MAPK Signaling: Mitogens 64
Show member pathways
 12.28 TP53 RB1 PTEN MET MDM2 IGF1R
32
Integrated Breast Cancer Pathway 1
12.19 TP53 RB1 PTEN MDM2 CDK4
33
Cellular senescence (KEGG) 36
12.18 TP53 RB1 PTEN MDM2 CDKN2A CDK4
34
Tyrosine Kinases / Adaptors 4
12.15 MET KIT IGF1R FRS2
35
Pathways in cancer 36
12.13 TP53 STAT6 RB1 PTEN PPARG MET
36
Direct p53 effectors 1
12.11 TP53 RB1 PTEN MET MDM2
37
Adipogenesis 1
12.1 STAT6 RB1 PPARG DDIT3 CEBPA
38
DNA Damage Response (only ATM dependent) 1
12.03 TP53 PTEN MDM2 CDKN2A
39
Small cell lung cancer 36
11.93 TP53 RB1 PTEN CDK4
40
Retinoblastoma (RB) in Cancer 1
11.89 TP53 RB1 MDM2 CDK4
41
Androgen receptor signaling pathway 1
11.87 RB1 PTEN MDM2
42
Senescence and Autophagy in Cancer 1
11.87 TP53 RB1 PTEN MDM2 IGF1R CDKN2A
43
Transcriptional misregulation in cancer 36
11.84 TP53 PPARG MET MDM2 IGF1R HMGA2
44
Bladder cancer 36 1
11.8 TP53 RB1 MDM2 CDKN2A CDK4
45
C-MYB transcription factor network 1
11.79 KIT CEBPA CD34
46
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.78 PPARG MYOG KIT DES CEBPA CD34
47
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.76 TP53 MDM2 CDKN2A
48
Platinum drug resistance 36
11.76 TP53 MDM2 CDKN2A
49
Central carbon metabolism in cancer 36
11.76 TP53 PTEN MET KIT
50
Glioblastoma Multiforme 63
11.75 TP53 RB1 PTEN MDM2 IGF1R CDKN2A
Sources

GO Terms for Dedifferentiated Liposarcoma

About this section

Cellular components related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.73 TP53 STAT6 RB1 PTEN PPARG MYOG
2 RNA polymerase II transcription factor complex GO:0090575 9.5 PPARG DDIT3 CEBPA
3 protein-DNA complex GO:0032993 9.43 MYOG HMGA2 DDIT3
4 senescence-associated heterochromatin focus GO:0035985 9.16 HMGA2 CDKN2A
5 transcription factor complex GO:0005667 9.1 TP53 RB1 MYOG DDIT3 CEBPA CDK4

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.22 TP53 STAT6 RB1 PPARG MYOG HMGA2
2 multicellular organism development GO:0007275 10.18 PPARG MYOG MET KIT IGF1R HMGA2
3 regulation of transcription by RNA polymerase II GO:0006357 10.13 TP53 STAT6 RB1 PPARG KIT DDIT3
4 response to drug GO:0042493 10 TP53 PTEN PPARG MDM2 CDK4
5 cell cycle GO:0007049 10 TP53 RB1 MYOG HMGA2 DDIT3 CDKN2A
6 negative regulation of transcription by RNA polymerase II GO:0000122 9.97 TP53 STAT6 RB1 PPARG MDM2 HMGA2
7 positive regulation of protein kinase B signaling GO:0051897 9.92 MET KIT IGF1R FRS2
8 regulation of cell cycle GO:0051726 9.91 TP53 RB1 PTEN CDK4
9 positive regulation of apoptotic process GO:0043065 9.91 TP53 PTEN PPARG HMGA2 CDKN2A CDK4
10 cell cycle arrest GO:0007050 9.89 TP53 RB1 DDIT3 CDKN2A
11 heart development GO:0007507 9.89 TP53 PTEN PPARG MDM2 MB
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 MET KIT IGF1R FRS2
13 regulation of cell proliferation GO:0042127 9.88 TP53 STAT6 KIT CEBPA CDK4
14 negative regulation of cell proliferation GO:0008285 9.87 TP53 RB1 PTEN PPARG MYOG CEBPA
15 positive regulation of transcription, DNA-templated GO:0045893 9.86 TP53 RB1 PPARG MYOG HMGA2 DDIT3
16 negative regulation of cell growth GO:0030308 9.85 TP53 RB1 PPARG CDKN2A
17 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 PTEN PPARG KIT DDIT3
18 positive regulation of kinase activity GO:0033674 9.82 MET KIT IGF1R
19 Ras protein signal transduction GO:0007265 9.81 TP53 RB1 CDKN2A
20 negative regulation of transcription, DNA-templated GO:0045892 9.76 TP53 RB1 PPARG MDM2 HMGA2 DDIT3
21 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.71 PTEN CEBPA CDKN2A
22 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.71 RB1 PTEN CDKN2A CDK4
23 positive regulation of cell cycle arrest GO:0071158 9.69 TP53 MYOG HMGA2
24 amyloid fibril formation GO:1990000 9.66 MDM2 CDKN2A
25 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.66 TP53 DDIT3
26 negative regulation of telomerase activity GO:0051974 9.65 TP53 PPARG
27 ER overload response GO:0006983 9.65 TP53 DDIT3
28 somatic stem cell division GO:0048103 9.65 KIT CDKN2A
29 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 TP53 STAT6 RB1 PPARG MYOG MET
30 cellular response to UV-C GO:0071494 9.63 TP53 MDM2
31 enucleate erythrocyte differentiation GO:0043353 9.61 RB1 MB
32 cellular response to actinomycin D GO:0072717 9.57 TP53 MDM2
33 senescence-associated heterochromatin focus assembly GO:0035986 9.56 HMGA2 CDKN2A
34 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN MDM2 KIT HMGA2 CEBPA

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.18 TP53 STAT6 RB1 PPARG MYOG HMGA2
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.01 TP53 STAT6 PPARG MYOG DDIT3 CEBPA
3 DNA-binding transcription factor activity GO:0003700 9.98 TP53 STAT6 RB1 PPARG MYOG DDIT3
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.93 TP53 STAT6 MYOG HMGA2 DDIT3 CEBPA
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.89 TP53 STAT6 RB1 PPARG MYOG
6 enzyme binding GO:0019899 9.88 TP53 RB1 PTEN PPARG MDM2
7 transcription regulatory region sequence-specific DNA binding GO:0000976 9.8 TP53 PPARG HMGA2 DDIT3 CEBPA
8 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 TP53 STAT6 MYOG HMGA2 DDIT3 CEBPA
9 transcription regulatory region DNA binding GO:0044212 9.77 TP53 PPARG HMGA2 DDIT3 CEBPA
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.69 MET KIT IGF1R
11 identical protein binding GO:0042802 9.65 TP53 STAT6 RB1 PTEN PPARG MET
12 protein phosphatase binding GO:0019903 9.56 TP53 STAT6 PPARG MET
13 disordered domain specific binding GO:0097718 9.46 TP53 RB1 MDM2 CDKN2A
14 transcription factor binding GO:0008134 9.23 TP53 RB1 PPARG HMGA2 DDIT3 CEBPA
Sources

Sources for Dedifferentiated Liposarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....